New evidence of the effectiveness of the Oxford / AstraZeneca vaccine, called “poor man’s vaccine”, the second that could enter circulation



[ad_1]

It is true that the Pfizer BioNTech and Moderna vaccines are approximately 95 percent effective, but flu vaccines are accepted 40-60% effective. The first results of the British-Swedish consortium’s vaccine trial showed an efficiency of more than 90 percent, but they were obtained by a procedural error, the volunteers had been injected with half a dose of vaccine, in the first phase.

“Sure, we’re still waiting for regulators to look into the data, but production is happening around the world, to make sure we have products that can be used, that can be distributed where they are needed, at refrigerator temperature, to reaching the most vulnerable people in society, ”said Andrew Pollard, director of the Oxford Vaccine Group.

As with Oxford’s Pfizer BionTech vaccine, Astra Zeneca could be approved for the first time in the UK in a few weeks. The first doses will be manufactured in Europe in Germany and the Netherlands, but there is also a large production capacity in Great Britain. It’s called the poor man’s vaccine, but it is the one that could save the planet, because it can be stored in normal refrigerators. Plus, the most successful formula immunizes in a single dose.

For the most important news of the day, broadcast in real time and presented equally, like our Facebook page!

Follow Mediafax on Instagram to see amazing images and stories from around the world!

The content of the website www.mediafax.ro is intended exclusively for your information and personal use. This prohibited republish the content of this site in the absence of an agreement from MEDIAFAX. To obtain this agreement, contact us at [email protected].



[ad_2]